thalidomide has been researched along with Carcinoma, Small Cell in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with thalidomide was not associated with a significant improvement in survival of SCLC patients." | 2.73 | Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. ( Breton, JL; David, P; Gameroff, S; Genève, J; Gervais, R; Janicot, H; Maraninchi, D; Pujol, JL; Quoix, E; Tanguy, ML; Westeel, V, 2007) |
| "The treatment with thalidomide was continued as maintenance for up to 2 years." | 2.73 | Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. ( Buchler, T; Ellis, P; Hackshaw, A; James, L; Lee, SM; Snee, M, 2008) |
| "Small cell lung cancer is a tumor that has a very poor prognosis without treatment." | 2.41 | Management of small cell lung cancer. ( Karapetis, C; Steer, C; Yip, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yip, D | 2 |
| Karapetis, C | 1 |
| Steer, C | 2 |
| Mall, JW | 1 |
| Philipp, AW | 1 |
| Mall, W | 1 |
| Pollmann, C | 1 |
| Chua, YJ | 1 |
| Pujol, JL | 2 |
| Riedel, RF | 1 |
| Crawford, J | 1 |
| Dunphy, F | 1 |
| Herndon, JE | 1 |
| Garst, J | 1 |
| Kelley, MJ | 1 |
| Breton, JL | 1 |
| Gervais, R | 1 |
| Tanguy, ML | 1 |
| Quoix, E | 1 |
| David, P | 1 |
| Janicot, H | 1 |
| Westeel, V | 1 |
| Gameroff, S | 1 |
| Genève, J | 1 |
| Maraninchi, D | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Lee, SM | 2 |
| James, L | 1 |
| Buchler, T | 1 |
| Snee, M | 1 |
| Ellis, P | 1 |
| Hackshaw, A | 1 |
| Rossi, A | 1 |
| Gridelli, C | 1 |
| Bria, E | 1 |
| Brock, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE[NCT00930891] | Phase 2/Phase 3 | 143 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial[NCT03062800] | Phase 2 | 232 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Carcinoma, Small Cell
| Article | Year |
|---|---|
Management of small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, S | 2001 |
Recent advances in management of small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2004 |
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Smal | 2002 |
3 trials available for thalidomide and Carcinoma, Small Cell
| Article | Year |
|---|---|
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Topics: Carcinoma, Small Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; M | 2007 |
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progress | 2008 |
4 other studies available for thalidomide and Carcinoma, Small Cell
| Article | Year |
|---|---|
Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Small Cell; Female; Humans; Neoplasm Metastasis; Survivors | 2002 |
[Is small cell lung cancer an orphan disease?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytoge | 2006 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |
Thalidomide in small-cell lung cancer: is it a tombstone?
Topics: Angiogenesis Inhibitors; Carcinoma, Small Cell; Disease-Free Survival; Humans; Lung Neoplasms; Survi | 2008 |